AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions

Naval Daver, Pau Montesinos, Ahmed Aribi, Giovanni Martinelli, Jessica K. Altman, Eunice S. Wang, Gail J. Roboz, Patrick W. Burke, Gianluca Gaidano, Roland B. Walter, Xavier Thomas, Deepa Jeyakumar, Daniel J. DeAngelo, Harry P. Erba, Elisabetta Todisco, Kebede Begna, Anjali Advani, Lauris Gastaud, Adolfo de la Fuente, Antonio CurtiLourdes M. Mendez, Paresh Vyas, Nicolas Boissel, Norbert Vey, Christian Recher, Thomas Longval, Uwe Platzbecker, Silke Kapp-Schwörer, Christoph Schliemann, Marina Konopleva, Laura Torres, David A. Sallman, Guido Marcucci, Giovanni Marconi, Hagop Kantarjian, Callum M. Sloss, Karen E. Malcolm, Patrick A. Zweidler-McKay, Kendra Sweet

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'AML-262 Pivekimab Sunirine (PVEK, IMGN632) Triplet With Azacitidine and Venetoclax Shows Broad Activity in Adverse Genetic Subsets of Relapsed/Refractory Acute Myeloid Leukemia and Reduced Infusion-Related Reactions'. Together they form a unique fingerprint.

Medicine & Life Sciences